SCHEMBL8352834

SCHEMBL8352834

CC(=O)Nc1ccc2nc(-c3ccccc3-c3nc4ccccc4[nH]3)[nH]c2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.67
▸ KDM4E B2RXH2 10/20 0.67
▸ HPGD P15428 6/20 0.67
▸ TP53 P04637 6/20 0.67
▸ SMN1; SMN2 Q16637 6/20 0.67
▸ HSD17B10 Q99714 5/20 0.67
▸ MEN1 O00255 4/20 0.67
▸ KMT2A Q03164 4/20 0.67
▸ POLB P06746 2/20 0.67
▸ RAB9A P51151 6/20 0.67
▸ NPC1 O15118 4/20 0.67
▸ THRB P10828 1/20 0.67
▸ GAA P10253 1/20 0.64
▸ MAPT P10636 3/20 0.63
▸ KLK7 P49862 1/20 0.63
▸ TDP1 Q9NUW8 1/20 0.56
▸ PABPC1 P11940 1/20 0.56
▸ LMNA P02545 1/20 0.55
▸ PKM P14618 1/20 0.54
▸ RXFP1 Q9HBX9 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4496122 0.88 KDM4E (0.61) ALDH1A1KDM4EHPGDTP53SMN1; SMN2
SCHEMBL1251122 0.88 ALDH1A1 (0.65) ALDH1A1KDM4EHPGDTP53SMN1; SMN2
SCHEMBL13203469 0.87 ALDH1A1 (0.67) ALDH1A1KDM4EHPGDTP53SMN1; SMN2
SCHEMBL13679600 0.86 ADORA2A (0.69) ALDH1A1KDM4EHPGDTP53SMN1; SMN2
SCHEMBL26551812 0.84 ALDH1A1 (0.83) ALDH1A1KDM4EHPGDTP53SMN1; SMN2
SCHEMBL13203481 0.83 ALDH1A1 (0.62) ALDH1A1KDM4EHPGDTP53SMN1; SMN2
SCHEMBL1899066 0.81 AURKA (0.64) ALDH1A1KDM4EHPGDTP53SMN1; SMN2
SCHEMBL2244714 0.81 HPSE (0.79) ALDH1A1KDM4EHPGDTP53SMN1; SMN2
SCHEMBL14090191 0.81 ALDH1A1 (0.60) ALDH1A1KDM4EHPGDTP53SMN1; SMN2
SCHEMBL2244254 0.81 KDM4E (1.00) ALDH1A1KDM4EHPGDTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482373-B2 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2009-01-27 — — US disclosed
US-7482373-B2 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2009-01-27 — — US disclosed
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2007-02-01 — — US disclosed
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2007-02-01 — — US disclosed
WO-2003094861-A2 BIS-BENZIMIDAZOLES AND RELATED COMPOUNDS AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2003-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNA3, KCNB2 ALDH1A1 2373/4885KDM4E 488/4885HPGD 3236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback